Cargando…

Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson’s Disease

The aim of this research was to prove the speculation that phenylxanthine (PX) derivatives possess adenosine A2A receptor (A2AR)-blocking properties and to screening and evaluate these PX derivatives as dual A2AR antagonists/MAO-B inhibitors for Parkinson′s disease. To explore this hypothesis, two s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xuebao, Han, Chao, Xu, Yong, Wu, Kaiqi, Chen, Shuangya, Hu, Mangsha, Wang, Luyao, Ye, Yun, Ye, Faqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152622/ https://www.ncbi.nlm.nih.gov/pubmed/28629145 http://dx.doi.org/10.3390/molecules22061010

Ejemplares similares

Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A(2B) adenosine receptor antagonists
por: Vlachodimou, Anna, et al.
Publicado: (2022)

MAO-inhibitors in Parkinson's Disease
por: Riederer, Peter, et al.
Publicado: (2011)

Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease
por: Duarte, Pablo, et al.
Publicado: (2022)

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
por: Finberg, John P. M., et al.
Publicado: (2016)

Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A(2A)AR Dual Binding Scaffold
por: Cruz-Monteagudo, Maykel, et al.
Publicado: (2017)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
por: Jost, Wolfgang H.
Publicado: (2022)

Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease
por: Krishna, Rakhee, et al.
Publicado: (2014)

Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs
por: Hagenow, Jens, et al.
Publicado: (2020)

In silico studies of natural product-like caffeine derivatives as potential MAO-B inhibitors/AA(2A)R antagonists for the treatment of Parkinson's disease
por: Boulaamane, Yassir, et al.
Publicado: (2022)

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
por: Teo, Kay Cheong, et al.
Publicado: (2013)

Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer
por: Xie, Zixin, et al.
Publicado: (2018)

Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis
por: Cho, Hyun-U, et al.
Publicado: (2021)

Design and Synthesis of New Benzothiazole Compounds as Selective hMAO-B Inhibitors
por: Ilgın, Sinem, et al.
Publicado: (2017)

Maó
por: Quintana, Josep M. (Josep Maria)
Publicado: (1996)

Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders
por: Koyiparambath, Vishal Payyalot, et al.
Publicado: (2021)

Identification of New N-methyl-piperazine Chalcones as Dual MAO-B/AChE Inhibitors
por: El-Damasy, Ashraf K., et al.
Publicado: (2023)

Design, Synthesis, and Biological Evaluation of Novel MAO-A Inhibitors Targeting Lung Cancer
por: Bardaweel, Sanaa, et al.
Publicado: (2022)

Synthesis, biological evaluation, and molecular docking of novel hydroxyzine derivatives as potential AR antagonists
por: Qi, Yueheng, et al.
Publicado: (2022)

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
por: Finberg, John P.M.
Publicado: (2010)

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
por: Giladi, Nir, et al.
Publicado: (2016)

Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson’s disease induced by the Japanese encephalitis virus
por: Minami, M., et al.
Publicado: (2006)

Mao : a biography /
por: Terrill, Ross
Publicado: (1981)

Mao Zedong
por: Grimm, Tilemann
Publicado: (1986)

Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
por: Regensburger, Martin, et al.
Publicado: (2023)

Design, Synthesis, and Biological Activity of Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine Derivatives as Anti-Inflammatory Agents
por: Zhang, Yuan, et al.
Publicado: (2017)

MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
por: Mallajosyula, Jyothi K., et al.
Publicado: (2008)

The Antiproliferative Effects of Flavonoid MAO Inhibitors on Prostate Cancer Cells
por: Zarmouh, Najla O., et al.
Publicado: (2020)

Microwave Assisted Organic Synthesis (MAOS) of Small Molecules as Potential HIV-1 Integrase Inhibitors
por: Ferro, Stefania, et al.
Publicado: (2011)

Synthesis, bioactivity, and molecular docking of novel arylpiperazine derivatives as potential AR antagonists
por: Qi, Yueheng, et al.
Publicado: (2022)

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson’s Disease
por: Nam, Min-Ho, et al.
Publicado: (2021)

Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review
por: Tsuboi, Takashi, et al.
Publicado: (2022)

Development of Isopropyl-Tailed Chalcones as a New Class of Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disorder
por: Kumar, Sunil, et al.
Publicado: (2023)

Synthesis of New Hydrazone Derivatives for MAO Enzymes Inhibitory Activity
por: Can, Nafiz Öncü, et al.
Publicado: (2017)

Correction: MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
por: Mallajosyula, Jyothi K., et al.
Publicado: (2012)

Design, Synthesis, In Vitro and In Silico Studies of New Thiazolylhydrazine-Piperazine Derivatives as Selective MAO-A Inhibitors
por: Sağlık, Begüm Nurpelin, et al.
Publicado: (2020)

Synthesis of Novel Benzo[b][1,6]naphthyridine Derivatives and Investigation of Their Potential as Scaffolds of MAO Inhibitors
por: Kulikova, Larisa N., et al.
Publicado: (2023)

Mao Tse-Tung
por: Payne, Robert
Publicado: (1972)

Mao Tse-tung
por: MacGregor-hastie, Roy

Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain
por: Fowler, Joanna S, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4s5mr17ivmoeudr2fsnvse1e4q